CureVac N.V. logo
CureVac N.V. CVAC

Quarterly report 2022-Q2
added 08-18-2022

report update icon

CureVac N.V. Balance Sheet 2011-2026 | CVAC

Annual Balance Sheet CureVac N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-783 M -1.27 B 35.8 M -21.4 M - - - - - - -

Long Term Debt

25.4 M - 65 M - - - - - - - -

Long Term Debt Current

3.47 M 3.23 M - - - - - - - - -

Total Non Current Liabilities

112 M 552 M 145 M 65.4 M - - - - - - -

Total Liabilities

470 M 800 M 173 M 93.6 M - - - - - - -

Deferred Revenue

- 158 M 7.48 M 5.78 M - - - - - - -

Retained Earnings

-1.06 B -645 M -516 M -416 M - - - - - - -

Total Assets

1.16 B 1.51 B 131 M 126 M - - - - - - -

Cash and Cash Equivalents

811 M 1.32 B 30.7 M 21.4 M - - - - - - -

Book Value

688 M 711 M -42.8 M 32.1 M - - - - - - -

Total Shareholders Equity

688 M 711 M -42.8 M 32.1 M - - - - - - -

All numbers in EUR currency

Quarterly Balance Sheet CureVac N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 35.9 M 36.6 M 25.4 M 25.7 M - - 26.9 M - - - 12.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - 107 M 114 M 112 M 154 M - - 552 M - - - 145 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 303 M 352 M 470 M 968 M - - 800 M - - - 173 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -1.13 B -1.07 B -1.06 B -1.05 B - - -645 M - - - -516 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 926 M 1.03 B 1.16 B 1.66 B - - 1.51 B - - - 131 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - 574 M 658 M 811 M 1.06 B - 1.5 B 1.32 B 892 M - - 30.7 M - - - 21.4 M - - - 99.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - 623 M 675 M 688 M 695 M - - 711 M - - - -42.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 623 M 675 M 688 M 695 M - 982 M 711 M 761 M - - -42.8 M - - - 32.1 M - - - 103 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Balance Sheet is a fundamental financial report of CureVac N.V., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
argenx SE argenx SE
ARGX
$ 700.45 -1.19 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.6 1.41 % $ 8.66 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.13 -5.06 % $ 105 M schweizSchweiz
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
$ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
$ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.6 -4.0 % $ 7.83 B israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA